{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:13:45Z","timestamp":1789683225100,"version":"4.0.1"},"reference-count":165,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The integration of nanotechnology into drug repurposing strategies is redefining the development landscape for diagnostic, therapeutic, and theranostic agents. In radiopharmacy, nanoplatforms are increasingly being explored to enhance or extend the use of existing radiopharmaceuticals, complementing earlier applications in other biomedical fields. Many of these nanoplatforms evolve into multifunctional systems by incorporating additional imaging modalities (e.g., MRI, fluorescence) or non-radioactive therapies (e.g., photodynamic therapy, chemotherapy). These hybrid constructs often emerge from the reformulation, repositioning, or revival of previously approved or abandoned compounds, generating entities with novel pharmacological, pharmacokinetic, and biodistribution profiles. However, their translational potential faces significant regulatory hurdles. Existing frameworks\u2014typically designed for single-modality drugs or devices\u2014struggle to accommodate the combined complexity of nanoengineering, radioactive components, and integrated functionalities. This review examines how these systems challenge current norms in classification, safety assessment, preclinical modeling, and regulatory coordination. It also addresses emerging concerns around digital adjuncts such as AI-assisted dosimetry and software-based therapy planning. Finally, the article outlines international initiatives aimed at closing regulatory gaps and provides future directions for building harmonized, risk-adapted frameworks that support innovation while ensuring safety and efficacy.<\/jats:p>","DOI":"10.3390\/pharmaceutics17091159","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:07:32Z","timestamp":1756901252000},"page":"1159","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy\u2014Implications for Radiopharmaceutical Repurposing (Beyond Oncology)"],"prefix":"10.3390","volume":"17","author":[{"given":"Mar\u00eda Jimena","family":"Salgueiro","sequence":"first","affiliation":[{"name":"Departamento de F\u00edsica, Facultad de Farmacia y Bioqu\u00edmica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina"},{"name":"Instituto de Tecnolog\u00eda Farmac\u00e9utica y Biofarmacia (InTecFyB), Universidad de Buenos Aires, Buenos Aires 1113, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7331-6722","authenticated-orcid":false,"given":"Marcela","family":"Zubillaga","sequence":"additional","affiliation":[{"name":"Departamento de F\u00edsica, Facultad de Farmacia y Bioqu\u00edmica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina"},{"name":"Instituto de Tecnolog\u00eda Farmac\u00e9utica y Biofarmacia (InTecFyB), Universidad de Buenos Aires, Buenos Aires 1113, Argentina"},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET), Buenos Aires 1113, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"ref_1","unstructured":"Ca\u00f1ellas, C.O., Salgueiro, M.J., and Zubillaga, M. (2025, June 18). Radiof\u00e1rmacos: Del Laboratorio al Paciente, Available online: http:\/\/hdl.handle.net\/11336\/107953."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"16","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/a-1650-9995","article-title":"Alpha emitting nuclides in nuclear medicine theranostics","volume":"61","author":"Miederer","year":"2022","journal-title":"Nuklearmedizin"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"Alpha-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2967\/jnumed.117.204651","article-title":"\u03b1-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2","volume":"59","author":"Poty","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_9","first-page":"17","article-title":"Reinventing pharma: The theranostic revolution","volume":"2","author":"Funkhouser","year":"2002","journal-title":"Curr. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kuge, Y., Shiga, T., and Tamaki, N. (2016). Perspectives on Nuclear Medicine for Molecular Diagnosis and Integrated Therapy, Springer Nature.","DOI":"10.1007\/978-4-431-55894-1"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","article-title":"Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: Workforce challenges and training in the age of theranostics","volume":"25","author":"Scott","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_12","unstructured":"McGuireWoods (2025, June 19). Radiopharmaceutical Industry Update: Q4 2024\u2013Q1 2025. Available online: https:\/\/www.mcguirewoods.com\/client-resources\/alerts\/2025\/4\/radiopharmaceutical-industry-update-q4-q1-2024-2025."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S1470-2045(24)00030-5","article-title":"Recent advances and impending challenges for the radiopharmaceutical sciences in oncology","volume":"25","author":"Lapi","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jalilian, A.R., Ocampo-Garc\u00eda, B., Pasanphan, W., Sakr, T.M., Melendez-Alafort, L., Grasselli, M., Lugao, A.B., Yousefnia, H., Dispenza, C., and Janib, S.M. (2022). IAEA Contribution to Nanosized Targeted Radiopharmaceuticals for Drug Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051060"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Trujillo-Nolasco, M., Morales-Avila, E., Cruz-Nova, P., Katti, K.V., and Ocampo-Garc\u00eda, B. (2021). Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13081123"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Klain, M., Zampella, E., Nappi, C., Nicolai, E., Ambrosio, R., Califaretti, E., Lamartina, L., Schlumberger, M., Deandreis, D., and Salvatore, D. (2021). Advances in Functional Imaging of Differentiated Thyroid Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194748"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1021\/acsnano.1c10550","article-title":"Transforming Nuclear Medicine with Nanoradiopharmaceuticals","volume":"16","author":"Roy","year":"2022","journal-title":"ACS Nano"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.biomaterials.2016.08.048","article-title":"Gold nanoparticles-based SPECT\/CT imaging probe targeting for vulnerable atherosclerosis plaques","volume":"108","author":"Li","year":"2016","journal-title":"Biomaterials"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.7150\/thno.20767","article-title":"Multimodality Imaging of Angiogenesis in a Rabbit Atherosclerotic Model by GEBP11 Peptide Targeted Nanoparticles","volume":"7","author":"Su","year":"2017","journal-title":"Theranostics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jcmg.2016.01.020","article-title":"In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models","volume":"9","author":"Binderup","year":"2016","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e010586","DOI":"10.1161\/CIRCIMAGING.120.010586","article-title":"Imaging Cardiovascular and Lung Macrophages With the Positron Emission Tomography Sensor 64Cu-Macrin in Mice, Rabbits, and Pigs","volume":"13","author":"Nahrendorf","year":"2020","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biomaterials.2015.01.016","article-title":"PET imaging of a collagen matrix reveals its effective injection and targeted retention in a mouse model of myocardial infarction","volume":"49","author":"Ahmadi","year":"2015","journal-title":"Biomaterials"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gomes-da-Silva, N.C., Xavier-de-Britto, I., Soares, M.A.G., Yoshihara, N.M.A., Ilem \u00d6zdemir, D., Ricci-Junior, E., Fechine, P.B.A., Alencar, L.M.R., Henriques, M.d.G.M.d.O., and Barja-Fidalgo, T.C. (2025). Nanostructured Lipoxin A4: Understanding Its Biological Behavior and Impact on Alzheimer\u2019s Disease (Proof of Concept). Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050649"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.2042-3306.2011.00403.x","article-title":"Intravenous technetium-99m labelled PEG-liposomes in horses: A safety and biodistribution study","volume":"44","author":"Underwood","year":"2012","journal-title":"Equine Vet. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ijpharm.2007.08.002","article-title":"Release profiles and morphological characterization by atomic force microscopy and photon correlation spectroscopy of 99mTechnetium-fluconazole nanocapsules","volume":"349","author":"Mosqueira","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.biopha.2018.01.021","article-title":"Biodistribution of free and encapsulated 99mTc-fluconazole in an infection model induced by Candida albicans","volume":"99","author":"Fuscaldi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: Current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","article-title":"Advances in PET imaging of Cancer","volume":"23","author":"Schwenck","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"1","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: A roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"263S","DOI":"10.2967\/jnumed.120.254532","article-title":"The future of nuclear medicine, molecular imaging, and theranostics","volume":"61","author":"Weber","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.crhy.2017.10.008","article-title":"The discovery of radioactivity","volume":"18","author":"Radvanyi","year":"2017","journal-title":"Comptes Rendus Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/bj0170439","article-title":"The absorption and translocation of lead by plants: A contribution to the application of the method of radioactive indicators in the investigation of the change of substance in plants","volume":"17","author":"Hevesy","year":"1923","journal-title":"Biochem. J."},{"key":"ref_36","first-page":"291","article-title":"Georg Charles de Hevesy: The father of nuclear medicine","volume":"24","author":"Myers","year":"1996","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1172\/JCI101129","article-title":"Studies on neoplasms with the aid of radioactive phosphorus. I. The total phosphorus metabolism of normal and leukemic mice","volume":"19","author":"Lawrence","year":"1940","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1172\/JCI101195","article-title":"Studies on neoplasms with the aid of radioactive phosphorus. II. The phosphorus metabolism of the nucleoprotein, phospholipid and acid soluble fractions of normal and leukemic mice","volume":"20","author":"Tuttle","year":"1941","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.112.2922.794.a","article-title":"The clinical use of radioactive isotopes","volume":"112","author":"Chamberlain","year":"1950","journal-title":"Science"},{"key":"ref_40","unstructured":"Beierwaltes, W.H., Johnson, P.C., and Solari, A.J. (1957). Clinical Use of Radioisotopes, W.B. Saunders Company."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2967\/jnumed.122.264144","article-title":"How many theranostics centers will we need in the united states?","volume":"63","author":"Czernin","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.2017170346","article-title":"Radiotheranostics in cancer diagnosis and management","volume":"286","author":"Jadvar","year":"2018","journal-title":"Radiology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2967\/jnumed.120.247197","article-title":"Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project","volume":"62","author":"Cutler","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41181-021-00123-2","article-title":"Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals","volume":"6","author":"Gillings","year":"2021","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.3645","article-title":"THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET\/CT to Personalized Radionuclide Therapy\u2014The Bad Berka Experience","volume":"2","author":"Baum","year":"2012","journal-title":"Theranostics"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"20170893","DOI":"10.1259\/bjr.20170893","article-title":"Recent advances in theranostics and challenges for the future","volume":"91","author":"Turner","year":"2018","journal-title":"Br. J. Radiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Poot, A.J., Lam, M.G.E.H., and van Noesel, M.M. (2020). The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.578286"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00259-022-05785-x","article-title":"Joint EANM, SNMMI and IAEA enabling guide: How to set up a theranostics centre","volume":"49","author":"Herrmann","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2967\/jnumed.123.265603","article-title":"Theranostics Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine","volume":"64","author":"Urbain","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2967\/jnumed.116.182899","article-title":"Operational and Dosimetric Aspects of Pediatric PET\/CT","volume":"58","author":"Fahey","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00259-022-05694-z","article-title":"EANM position on the in-house preparation of radiopharmaceuticals","volume":"49","author":"Hendrikse","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_52","unstructured":"International Atomic Energy Agency (2025, July 03). Database of Cyclotrons for Radionuclide Production. Available online: https:\/\/nucleus.iaea.org\/sites\/accelerators\/Pages\/Cyclotron.aspx."},{"key":"ref_53","unstructured":"International Atomic Energy Agency (2025, July 03). Disposal of radioactive waste. IAEA Safety Standards Series No. SSR-5, Vienna, Available online: https:\/\/www-pub.iaea.org\/MTCD\/Publications\/PDF\/Pub1449_web.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","article-title":"Medical imaging and nuclear medicine: A Lancet Oncology Commission","volume":"22","author":"Hricak","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1007\/s00259-021-05444-7","article-title":"Changes in the global impact of COVID-19 on nuclear medicine departments during 2020: An international follow-up survey","volume":"48","author":"Giammarile","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00259-021-05331-1","article-title":"Medical imaging in times of pandemic: Focus on the cornerstones of successful imaging","volume":"48","author":"Erba","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.semnuclmed.2021.06.019","article-title":"Nuclear Medicine Departments in the Era of COVID-19","volume":"52","author":"Paez","year":"2022","journal-title":"Semin. Nucl. Med."},{"key":"ref_58","unstructured":"International Atomic Energy Agency (2025, July 03). Research Reactor Database (RRDB). Available online: https:\/\/nucleus.iaea.org\/rrdb\/#\/home."},{"key":"ref_59","unstructured":"International Atomic Energy Agency (2025, July 03). Manual for Reactor Produced Radioisotopes, IAEA-TECDOC-1340, Vienna. Available online: https:\/\/www-pub.iaea.org\/MTCD\/publications\/PDF\/te_1340_web.pdf."},{"key":"ref_60","unstructured":"International Atomic Energy Agency (2025, July 03). Predisposal Management of Radioactive Waste from the Use of Radioactive Material in Medicine, Industry, Agriculture, Research and Education. IAEA Safety Standards Series No. SSG-45, Vienna. Available online: https:\/\/www.iaea.org\/publications\/11087\/predisposal-management-of-radioactive-waste-from-the-use-of-radioactive-material-in-medicine-industry-agriculture-research-and-education."},{"key":"ref_61","unstructured":"(2025, July 03). International Atomic Energy Agency. Management of Radioactive Waste from the Use of Radionuclides in Medicine, IAEA-TECDOC-1805, Vienna, Available online: https:\/\/www-pub.iaea.org\/MTCD\/Publications\/PDF\/te_1183_prn.pdf."},{"key":"ref_62","unstructured":"International Atomic Energy Agency (2025, July 03). Radiation Protection and Safety in Medical Uses of Ionizing Radiation, IAEA Safety Standards Series No. SSG-46, Vienna 2018. Available online: https:\/\/www.iaea.org\/publications\/11102\/radiation-protection-and-safety-in-medical-uses-of-ionizing-radiation."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2018.08.008","article-title":"Radiopharmaceutical enhancement by drug delivery systems: A review","volume":"287","author":"Kleynhans","year":"2018","journal-title":"J. Control Release"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2967\/jnmt.116.185454","article-title":"Potential Ways to Address Shortage Situations of 99Mo\/99mTc","volume":"45","author":"Filzen","year":"2017","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Skliarova, H., Cisternino, S., Cicoria, G., Marengo, M., and Palmieri, V. (2018). Innovative Target for Production of Technetium-99m by Biomedical Cyclotron. Molecules, 24.","DOI":"10.3390\/molecules24010025"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1023\/A:1011993913566","article-title":"Economics of drug delivery","volume":"15","author":"Chess","year":"1998","journal-title":"Pharm. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: Entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"key":"ref_68","first-page":"1","article-title":"Targeted drug delivery: A review","volume":"6","author":"Mishra","year":"2016","journal-title":"Am. J. Pharmatech. Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sercombe, L., Veerati, T., Moheimani, F., Wu, S.Y., Sood, A.K., and Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00286"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1080\/10717544.2016.1177136","article-title":"Pharmaceutical liposomal drug delivery: A review of new delivery systems and a look at the regulatory landscape","volume":"23","author":"Zylberberg","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1242477","DOI":"10.1126\/science.1242477","article-title":"Nonadditivity of nanoparticle interaction","volume":"350","author":"Batista","year":"2015","journal-title":"Science"},{"key":"ref_72","first-page":"1184","article-title":"Kapoor BMicrosphere: A review","volume":"1","author":"Sahil","year":"2011","journal-title":"Int. J. Res. Pharm. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2967\/jnumed.109.068312","article-title":"A bridge not too far: Linking disciplines through molecular imaging probes","volume":"44","author":"Valliant","year":"2016","journal-title":"J. Nucl. Med. Tech."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s12350-011-9379-7","article-title":"Reduced isotope dose and imaging time with a high-efficiency CZT SPECT camera","volume":"18","author":"Duvall","year":"2011","journal-title":"J. Nucl. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.apradiso.2013.11.100","article-title":"Reduce, reuse and recycle: A green solution to Canada\u2019s medical isotope shortage","volume":"87","author":"Galea","year":"2014","journal-title":"Appl. Radiat. Isot."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/08929882.2015.1037123","article-title":"The production of medical isotopes without nuclear reactors or uranium enrichment","volume":"23","author":"Hoedl","year":"2015","journal-title":"Sci. Glob. Secur."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: Combining imaging and therapy","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1586\/erm.13.15","article-title":"Nanotheranostics for personalized medicine","volume":"13","author":"Kim","year":"2013","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"28919","DOI":"10.1039\/C6RA01135G","article-title":"Targeted theranostic liposomes: Rifampicin and ofloxacin loaded pegylated liposomes for theranostic application in mycobacterial infections","volume":"6","author":"Kaul","year":"2016","journal-title":"RSC Adv."},{"key":"ref_80","first-page":"1752","article-title":"Intratumoral injection of rhenium-188 microspheres into an animal model of hepatoma","volume":"39","author":"Wang","year":"1998","journal-title":"J. Nucl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.apradiso.2004.11.003","article-title":"Labelling and biodistribution of different particle materials for radioembolization therapy with 188Re","volume":"62","author":"Wunderlich","year":"2005","journal-title":"Appl. Radiat. Isot."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1109\/23.531891","article-title":"Attenuation correction of SPECT using x-ray CT on an Emission-Transmission CT System: Myocardial perfusion assessment","volume":"43","author":"Blankespoor","year":"1996","journal-title":"IEEE Trans. Nucl. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1088\/0031-9155\/42\/10\/010","article-title":"Simultaneous PET and MR imaging","volume":"42","author":"Shao","year":"1997","journal-title":"Phys. Med. Biol."},{"key":"ref_84","first-page":"1369","article-title":"A combined PET\/CT scanner for clinical oncology","volume":"41","author":"Beyer","year":"2000","journal-title":"J. Nucl. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2967\/jnumed.108.051276","article-title":"Dual-modality imaging: Combining anatomy and function","volume":"49","author":"Townsend","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_86","first-page":"78S","article-title":"Improvements in cancer staging with PET\/CT: Literature-based evidence as of September 2006","volume":"48","author":"Czernin","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm1700","article-title":"Simultaneous PET-MRI: A new approach for functional and morphological imaging","volume":"14","author":"Judenhofer","year":"2008","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1021\/ar800045c","article-title":"Synergistically integrated nanoparticles as multimodal probes for nanobiotechnology","volume":"41","author":"Cheon","year":"2008","journal-title":"ACC. Chem. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/153303461000900102","article-title":"Combined PET\/MR imaging\u2014Technology and applications","volume":"9","author":"Wehrl","year":"2010","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2967\/jnumed.111.092726","article-title":"Performance measurements of the Siemens mMR integrated whole-body PET\/MR scanner","volume":"52","author":"Delso","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_91","first-page":"493","article-title":"Hybrid fluorescence, PET, and CT for small animal imaging","volume":"53","author":"Tan","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_92","unstructured":"Committee on State of Molybdenum-99 Production and Utilization and Progress Toward Eliminating Use of Highly Enriched Uranium, Nuclear and Radiation Studies Board, Division on Earth and Life Studies, and National Academies of Sciences, Engineering, and Medicine (2016). Molybdenum-99 for Medical Imaging."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.addr.2019.05.012","article-title":"Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine","volume":"143","author":"Man","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Mushtaq, S., Bibi, A., Park, J.E., and Jeon, J. (2021). Recent Progress in Technetium-99m-Labeled Nanoparticles for Molecular Imaging and Cancer Therapy. Nanomaterials, 11.","DOI":"10.3390\/nano11113022"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Toro-Gonz\u00e1lez, M., Akingbesote, N., Bible, A., Pal, D., Sanders, B., Ivanov, A.S., Jansone-Popova, S., Popovs, I., Benny, P., and Perry, R. (2024). Development of 225Ac-doped biocompatible nanoparticles for targeted alpha therapy. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-024-02520-6"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1515\/ract-2019-3206","article-title":"Encapsulation and retention of 225Ac, 223Ra, 227Th, and decay daughters in zircon-type gadolinium vanadate nanoparticles","volume":"108","author":"Dame","year":"2020","journal-title":"Radiochim. Acta"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/bc100574f","article-title":"LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides","volume":"22","author":"Woodward","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1080\/17435889.2024.2368454","article-title":"Radiolabeling of bionanomaterials with technetium 99m: Current state and future prospects","volume":"19","author":"Trusova","year":"2024","journal-title":"Nanomedicine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acm2.13421","article-title":"A case study of cost-benefit analysis in occupational radiological protection within the healthcare system of Sweden","volume":"22","author":"Isaksson","year":"2021","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1039\/D0CS00384K","article-title":"Radiolabelling of nanomaterials for medical imaging and therapy","volume":"50","author":"Pellico","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.122.264900","article-title":"Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy","volume":"64","author":"Pomykala","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1007\/s00259-021-05345-9","article-title":"EANM position paper on the role of radiobiology in nuclear medicine","volume":"48","author":"Aerts","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Blanc-B\u00e9guin, F., Damien, P., Floch, R., Kerleguer, K., Hennebicq, S., Robin, P., Sala\u00fcn, P.Y., and Le Roux, P.Y. (2022). Radiation exposure to nuclear medicine technologists performing a V\/Q PET: Comparison with conventional V\/Q scintigraphy, [18F]FDG PET and [68Ga]Ga DOTATOC PET procedures. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1051249"},{"key":"ref_104","first-page":"255","article-title":"Radiotheranostics in oncology: Making precision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2967\/jnmt.119.230516","article-title":"Radiation Exposure to the Nuclear Medicine Personnel During Preparation and Handling of 213Bi-Radiopharmaceuticals","volume":"48","author":"Thakral","year":"2020","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1021\/acsnano.7b07252","article-title":"Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics","volume":"12","author":"Ehlerding","year":"2018","journal-title":"ACS Nano"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1049\/nbt2.12021","article-title":"Recent nanotheranostics applications for cancer therapy and diagnosis: A review","volume":"15","author":"Aminolroayaei","year":"2021","journal-title":"IET Nanobiotechnol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s10238-023-01262-3","article-title":"Recent nanotheranostic approaches in cancer research","volume":"24","author":"Gupta","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-4939-6591-5_13","article-title":"Techniques for loading technetium-99m and rhenium-186\/188 radionuclides into preformed liposomes for diagnostic imaging and radionuclide therapy","volume":"1522","author":"Goins","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00259-002-1038-4","article-title":"In vitro and in vivo study of 99mTc-MIBI encapsulated in PEG-liposomes: A promising radiotracer for tumour imaging","volume":"30","author":"Briane","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_112","first-page":"1491","article-title":"Use of technetium-99m-liposomes in tumour imaging","volume":"35","author":"Goins","year":"1994","journal-title":"J. Nucl. Med."},{"key":"ref_113","first-page":"622","article-title":"99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: Clinical evaluation","volume":"41","author":"Dams","year":"2000","journal-title":"J. Nucl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"115 Dagar, S., Krishnadas, A., Rubinstein, I., Blend, M.J., and Onyuksel, H. (2003). VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In Vivo studies. J. Control. Release, 91, 123\u2013133.","DOI":"10.1016\/S0168-3659(03)00242-6"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1158\/1078-0432.CCR-06-0839","article-title":"A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation","volume":"15","author":"Kleiter","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_116","first-page":"65","article-title":"MicroSPECT\/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome n human colorectal adenocarcinoma-bearing mice","volume":"30","author":"Chen","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_117","first-page":"2607","article-title":"Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in a C26 colonic peritoneal carcinomatosis mice","volume":"6","author":"Tsai","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/jat.1541","article-title":"Preliminary evaluation of acute toxicity of 188Re-BMEDA-liposome in rats","volume":"30","author":"Liu","year":"2010","journal-title":"J. Appl. Toxicol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jat.2751","article-title":"Extended acute toxicity study of 188Re-liposome in rats","volume":"33","year":"2013","journal-title":"J. Appl. Toxicol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nucmedbio.2014.05.142","article-title":"The PEGylated liposomal doxorubicin improves the delivery and therapeutic efficiency of 188Re-Liposome by modulating phagocytosis in C26 murine colon carcinoma tumour mode","volume":"41","author":"Hsu","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"ref_121","first-page":"3641","article-title":"External beam radiotherapy synergizes 188Re-liposome against human oesophageal cancer xenograft and modulates 188Re-liposome pharmacokinetics","volume":"10","author":"Chang","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s00259-008-0735-z","article-title":"188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas","volume":"35","author":"Allard","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1158\/1078-0432.CCR-07-4149","article-title":"Intraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model","volume":"14","author":"Wang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1080\/10611860802230372","article-title":"Imaging of 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis","volume":"16","author":"Zavaleta","year":"2008","journal-title":"J. Drug Target."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3892\/or.2012.1978","article-title":"Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BNN in AR42J pancreatic tumour-bearing mice","volume":"28","author":"Chang","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nucmedbio.2011.06.010","article-title":"Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-Fu in a CT26-luc lung-metastatic mice model","volume":"39","author":"Chen","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/neuonc\/nos060","article-title":"Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma","volume":"14","author":"Phillips","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_128","first-page":"678","article-title":"Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxurbicin in a 4T1 murine orthotopic breast cancer model","volume":"5","author":"Liu","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.radonc.2016.02.007","article-title":"Intraperitoneal (188)Re-liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice","volume":"119","author":"Shen","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jmmm.2003.10.022","article-title":"Preparation and radiolabeling of surface-modified magnetic nanoparticles with rhenium-188 for magnetic targeted radiotherapy","volume":"277","author":"Cao","year":"2004","journal-title":"J. Magn. Magn. Mater."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10967-006-0223-5","article-title":"Synthesis of amino-modified magnetite nanoparticles coated with Hepama-1 and radiolabeled with 188Re for bio-magnetically targeted radiotherapy","volume":"269","author":"Liang","year":"2006","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"17024","DOI":"10.1038\/natrevmats.2017.24","article-title":"Rethinking cancer nanotheranostics","volume":"2","author":"Chen","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"14290","DOI":"10.1021\/acsomega.2c07840","article-title":"Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities","volume":"8","author":"Kashyap","year":"2023","journal-title":"ACS Omega"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12935-024-03610-z","article-title":"A state-of-the-art review of the recent advances of theranostic liposome hybrid nanoparticles in cancer treatment and diagnosis","volume":"25","author":"Azimizonuzi","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Karageorgou, M.A., Bouziotis, P., Stiliaris, E., and Stamopoulos, D. (2023). Radiolabeled Iron Oxide Nanoparticles as Dual Modality Contrast Agents in SPECT\/MRI and PET\/MRI. Nanomaterials, 13.","DOI":"10.3390\/nano13030503"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11095-012-0929-8","article-title":"89Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer","volume":"30","author":"Abou","year":"2013","journal-title":"Pharm. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"20523","DOI":"10.1021\/acsanm.3c04269","article-title":"Radiolabeled iron oxide nanomaterials for multimodal nuclear imaging and positive contrast MRI","volume":"6","author":"Pellico","year":"2023","journal-title":"ACS Appl. Nano Mater."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1007\/s10967-022-08431-w","article-title":"Preparation and in vivo imaging of a novel potential \u03b1v\u03b23 targeting PET\/MRI dual-modal imaging agent","volume":"331","author":"Shi","year":"2022","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1021\/bc900511j","article-title":"In Vivo evaluation of 64Cu-labeled magnetic nanoparticles as a dual-modality PET\/MR imaging agent","volume":"21","author":"Glaus","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/bc300175d","article-title":"A novel multifunctional theranostic liposome drug delivery system: Construction, characterization, and multimodality MR, Near-infrared fluorescent and nuclear imaging","volume":"23","author":"Li","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"ref_142","first-page":"520","article-title":"Lanthanide-loaded liposomes for multimodality imaging and therapy","volume":"21","author":"Zielhuis","year":"2006","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","article-title":"Nanoparticles in medicine: Therapeutic applications and developments","volume":"83","author":"Zang","year":"2008","journal-title":"Clin. Pharm. Therap."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","article-title":"Challenges in development of targeted liposomal therapeutics","volume":"14","author":"Sawant","year":"2012","journal-title":"AAPS J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0005-2736(94)90038-8","article-title":"Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes","volume":"1190","author":"Litzinger","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.addr.2012.04.010","article-title":"Nanoparticles in drug delivery: Past, present and future","volume":"65","author":"Couvreur","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2016.02.021","article-title":"Sonoporation enhances liposome accumulation and penetration in tumors with low EPR","volume":"231","author":"Theek","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S1359-6446(05)03698-6","article-title":"Essential properties of drug-targeting delivery systems","volume":"10","author":"Petrak","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical application","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity and distinct tumor imaging in vivo","volume":"65","author":"Meada","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementarty phase I studies","volume":"13","author":"Uriely","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.addr.2012.11.006","article-title":"Pharmacokinetic considerations for targeted drug delivery","volume":"65","author":"Yamashita","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: Bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","article-title":"Production and regulatory issues for theranostics","volume":"25","author":"Giammarile","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41578-023-00581-x","article-title":"New Opportunities and Old Challenges in the Clinical translation of Nanotheranostics","volume":"8","author":"Gawne","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Kostev\u0161ek, N., Cheung, C.C.L., Ser\u0161a, I., Kreft, M.E., Monaco, I., Comes Franchini, M., Vidmar, J., and Al-Jamal, W.T. (2020). Magneto-Liposomes as MRI Contrast Agents: A Systematic Study of Different Liposomal Formulations. Nanomaterials, 10.","DOI":"10.3390\/nano10050889"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1039\/D3TB00187C","article-title":"Development of cationic peptide-based hydrogels loaded with iopamidol for CEST-MRI detection","volume":"11","author":"Rosa","year":"2023","journal-title":"J. Mater. Chem. B"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1021\/acsami.2c22985","article-title":"Novel Design and Application of High-NA Fiber Imaging Bundles for In Vivo Brain Imaging with Two-Photon Scanning Fluorescence Microscopy","volume":"15","author":"Bijoch","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Gallo, E., Diaferia, C., Balasco, N., Sibillano, T., Roviello, V., Giannini, C., Vitagliano, L., Morelli, G., and Accardo, A. (2021). Fabrication of fluorescent nanospheres by heating PEGylated tetratyrosine nanofibers. Sci. Rep., 11.","DOI":"10.1038\/s41598-020-79396-7"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Khalid, A., and Tomljenovic-Hanic, S. (2024). Emerging Fluorescent Nanoparticles for Non-Invasive Bioimaging. Molecules, 29.","DOI":"10.3390\/molecules29235594"},{"key":"ref_162","unstructured":"(2025, July 03). EMA-Innovation Task Force Briefing Meetings. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/innovation-task-force-briefing-meetings."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1208\/s12248-014-9701-9","article-title":"Summary report of PQRI Workshop on Nanomaterial in Drug Products: Current experience and management of potential risks","volume":"17","author":"Bartlett","year":"2015","journal-title":"AAPS J."},{"key":"ref_164","unstructured":"(2025, July 03). FDA 2021 NCTR Research Highlights and Accomplishments, Available online: https:\/\/www.fda.gov\/about-fda\/nctr-publications\/2021-nctr-research-highlights."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Chang, C.H., Chang, M.C., Chang, Y.J., Chen, L.C., Lee, T.W., and Ting, G. (2021). Translating Research for the Radiotheranostics of Nanotargeted 188Re-Liposome. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083868"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/9\/1159\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:38:49Z","timestamp":1760035129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/9\/1159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":165,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["pharmaceutics17091159"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17091159","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}